Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 11/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697196 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4ESMN1; SMN2TYK2LMNA | |
| SCHEMBL21948000 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4ESMN1; SMN2TYK2LMNA | |
| SCHEMBL20697368 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4ESMN1; SMN2TYK2LMNA | |
| SCHEMBL21258629 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4ESMN1; SMN2TYK2LMNA | |
| SCHEMBL21948446 | 0.84 | ALDH1A1 (0.41) | ALDH1A1KDM4ESMN1; SMN2TYK2LMNA | |
| SCHEMBL20689411 | 0.84 | TYK2 (0.43) | ALDH1A1KDM4ESMN1; SMN2TYK2LMNA | |
| SCHEMBL21258587 | 0.84 | TYK2 (0.43) | ALDH1A1KDM4ESMN1; SMN2TYK2LMNA | |
| SCHEMBL20689433 | 0.84 | TYK2 (0.45) | ALDH1A1KDM4ETYK2BRD4 | |
| SCHEMBL21238673 | 0.84 | TYK2 (0.45) | ALDH1A1KDM4ETYK2BRD4 | |
| SCHEMBL24584927 | 0.82 | ALDH1A1 (0.43) | ALDH1A1KDM4ESMN1; SMN2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885KDM4E 391/4885SMN1; SMN2 1145/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885KDM4E 391/4885SMN1; SMN2 1145/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885KDM4E 391/4885SMN1; SMN2 1145/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885KDM4E 391/4885SMN1; SMN2 1145/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885KDM4E 391/4885SMN1; SMN2 1145/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885KDM4E 391/4885SMN1; SMN2 1145/4885 |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885KDM4E 391/4885SMN1; SMN2 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.